EN DE

Anagenics Limited (AN1) Fair Value & Analysis

Consumer Defensive · AU · Market cap A$5.9M

AL Anagenics Limited AN1 · AU
PriceA$0.0070
Fair ValueA$0.0053
Upside-24.3%
Quality42/100
Watch Anagenics Limited for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Loss-making · -13.4% net margin
Low debt · negative free cash flow
Trails peers (2/11)
Narrow moat 16/100
Evidence: Low Share as image

Fair value as of: Jul 19, 2026

From 3 valuation models · updated 22 days ago

Below-average quality, and screening another 24% overvalued on our models.

What matters now

  • Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

A$0.1153 A$0.0040 Fair Value A$0.0053 Aug 2020 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range A$0.0040 – A$0.1153 · the A$0.0070 price screens above the A$0.0053 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Anagenics Limited (AN1) currently trades at A$0.0070, while our model-based Fair Value estimate is A$0.0053, implying the stock looks roughly 24.3% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Anagenics Limited generated revenue of A$4.8M at a net margin of -13.4%. Revenue declined 10.0% year over year. It earns a return on equity of -28.5%. Fundamentals as of Jul 19, 2026

The share trades about 22% below its 52-week high and 75% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -24%, AN1 screens cheaper than that median.

Notify me when AN1 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) A$4.8M
Revenue growth (YoY) -10.0%
Net margin -13.4%
Return on equity -28.5%
Free cash flow −A$1.6M FY2025
Operating margin 6.8%
More key figures
Net debt A$453K FY2025

Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 42/100

Of which business quality 43 · Market factors (momentum, volatility) 63

Profitability 36
Margins and returns on capital today
Quality Growth 55
Are margins and returns improving?
Cashflow 38
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 69
Price trend over the last 3–12 months (market factor)
52W Momentum 69
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name.

Full company description

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Anagenics Limited reported revenue of A$4.7M in FY2025 versus A$5.8M in FY2021, a compound −5.0%/yr. Reported net income was −A$1.2M in FY2025.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
A$4.7M
Latest YoY
−56.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−11.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.5%
Avg. growth/yr (14Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+43.1%
Revenue −5.0%/yr
FY21 A$5.8M
FY22 A$6.9M
FY23 A$9.1M
FY24 A$10.8M
FY25 A$4.7M
Net income
FY21 −A$3.4M
FY22 −A$3.6M
FY23 −A$2.7M
FY24 −A$7.5M
FY25 −A$1.2M

AN1 screens 24% overvalued. Compare with The Procter & Gamble Company →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Anagenics Limited Fair Value". https://www.fairvalue-calculator.com/stock/AN1

Peer Group

Household & Personal Products · 244 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 42 · Bottom 25%
Fair Value upside −24% · Below median
Return on assets -0% · Bottom 25%
Net margin (TTM) -13% · Bottom 25%
Operating margin (TTM) 7% · Below median
Revenue growth -10% · Bottom 25%

Valuation Multiples vs Household & Personal Products median · lower = cheaper

P/B 2.29× · Pricier than median
P/S (TTM) 0.87× · Cheaper than median
EV/EBITDA 19.0× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 1 · sector 28
FUTURE 0 · sector 4
PAST 0 · sector 26
HEALTH 100 · sector 98
DIVIDEND 0 · sector 50

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
The Procter & Gamble Company PG $146.80 $108.16 -26%
Unilever PLC ULN 1,080 MXN 1,273 MXN +18%
Hindustan Unilever Limited HINDUNILVR ₹2,144 ₹1,000 -53%
Essity AB ESSITYA kr 279.00 kr 250.02 -10%
Godrej Consumer Products Limited GODREJCP ₹1,088 ₹367.64 -66%
Marico Limited MARICO ₹846.75 ₹233.05 -72%
APR Co 278470 375,000 KRW 151,222 KRW -60%
Dabur India Limited DABUR ₹429.45 ₹181.60 -58%
Kimberly-Clark de México, S. A. B. de C. V., KIMBERA 38.07 MXN 50.09 MXN +32%
PT Unilever Indonesia Tbk UNVR 1,730 IDR 1,934 IDR +12%

Compare Anagenics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Anagenics Limited (AN1) overvalued or undervalued?
As of Jul 19, 2026, our model estimates a fair value of A$0.0053 versus a price of A$0.0070, about −24% (overvalued).
What is the fair value of AN1?
Our model-based fair value for Anagenics Limited is A$0.0053 (as of Jul 19, 2026), built from audited fundamentals. The current price is A$0.0070.
What is the quality score of AN1?
Anagenics Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Anagenics Limited (AN1)?
Anagenics Limited reported trailing-twelve-month revenue of about A$4.8M (latest available figure, as of Jul 19, 2026).
What is the net profit margin of AN1?
The net profit margin of Anagenics Limited is about -13.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Anagenics Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.